2022-001040-23: Treatment of relapsed or refractory B-cell lymphoma with CAR-T therapy produced by a new technology. Tratamiento del linfoma de células B en recaída o refractario con terapia CAR-T producida por una nueva tecnología. |
|
|
| Not yet recruiting | 1/2 | 27 | Europe | TranspoCART19, Cyclophosphamide, Fludarabina, Bendamustina, Tocilizumab, Cetuximab, Injection/infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, , Genoxal 25mg/ml, Fludarabina Teva 25 mg/ml, Bendamustina Tillomed 2,5 mg/ml, RoActemra 20 mg/m, Erbitux 5 mg/ml | Instituto de Investigación Biomédica de Salamanca (IBSAL) - IECSCYL, Instituto de Salud Carlos III | Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Diseases [C] - Cancer [C04] | | | | |
CC-95251-ST-001, NCT03783403: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers |
|
|
| Terminated | 1 | 206 | Europe, Canada, US, RoW | CC-95251, Rituximab, Cetuximab | Celgene | Neoplasms | 08/24 | 08/24 | | |
